APO RESEARCH · REPORT
10-Valent Pneumococcal Polysaccharide Vaccine
10-Valent Pneumococcal Polysaccharide Vaccine is a vaccine product category defined by its pneumococcal antigen composition and formulation.

Product & engineering
Understand the product.
Antigen composition, conjugation status, presentation and labelled indications distinguish supplied vaccines. Products with different compositions are not interchangeable solely because a headline count is similar.
The commercial boundary
The selected edition describes a market scope. Product approvals, labelled use and clinical acceptance require their own evidence; neither report segmentation nor an illustrative image establishes medical suitability.
Which antigen composition and formulation define the vaccine?
Antigen composition, conjugation status, presentation and labelled indications distinguish supplied vaccines. Products with different compositions are not interchangeable solely because a headline count is similar.
Selected research
Market Outlook & Growth Opportunities
Global 10-Valent Pneumococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026
Market perspective
The global 10-Valent Pneumococcal Polysaccharide Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for 10-Valent Pneumococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for 10-Valent Pneumococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for 10-Valent Pneumococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the 10-Valent Pneumococcal Polysaccharide Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the 10-Valent Pneumococcal Polysaccharide Vaccine market include GSK. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global 10-Valent Pneumococcal Polysaccharide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of 10-Valent Pneumococcal Polysaccharide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents 10-Valent Pneumococcal Polysaccharide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the 10-Valent Pneumococcal Polysaccharide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.
10-Valent Pneumococcal Polysaccharide Vaccine Segment by Company
GSK
10-Valent Pneumococcal Polysaccharide Vaccine Segment by Type
Single Dose Vial
Pre-filled Syringe
10-Valent Pneumococcal Polysaccharide Vaccine Segment by Application
Hospital
Clinic
10-Valent Pneumococcal Polysaccharide Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global 10-Valent Pneumococcal Polysaccharide Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions 10-Valent Pneumococcal Polysaccharide Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify 10-Valent Pneumococcal Polysaccharide Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze 10-Valent Pneumococcal Polysaccharide Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 10-Valent Pneumococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of 10-Valent Pneumococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 10-Valent Pneumococcal Polysaccharide Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the 10-Valent Pneumococcal Polysaccharide Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global 10-Valent Pneumococcal Polysaccharide Vaccine industry.
Chapter 3: Detailed analysis of 10-Valent Pneumococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of 10-Valent Pneumococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of 10-Valent Pneumococcal Polysaccharide Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Single Dose Vial
- Pre-filled Syringe
Applications
- Hospital
- Clinic
Companies covered
- GSK
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
- 1.2.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Volume (2021-2032)
- 1.2.3 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 10-Valent Pneumococcal Polysaccharide Vaccine Market Dynamics
- 2.1 10-Valent Pneumococcal Polysaccharide Vaccine Industry Trends
- 2.2 10-Valent Pneumococcal Polysaccharide Vaccine Industry Drivers
- 2.3 10-Valent Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges
- 2.4 10-Valent Pneumococcal Polysaccharide Vaccine Industry Restraints
3 10-Valent Pneumococcal Polysaccharide Vaccine Market by Company
- 3.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Company Revenue Ranking in 2025
- 3.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Revenue by Company (2021-2026)
- 3.3 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Company (2021-2026)
- 3.4 Global 10-Valent Pneumococcal Polysaccharide Vaccine Average Price by Company (2021-2026)
- 3.5 Global 10-Valent Pneumococcal Polysaccharide Vaccine Company Ranking (2024-2026)
- 3.6 Global 10-Valent Pneumococcal Polysaccharide Vaccine Company Manufacturing Base and Headquarters
- 3.7 Global 10-Valent Pneumococcal Polysaccharide Vaccine Company Product Type and Application
- 3.8 Global 10-Valent Pneumococcal Polysaccharide Vaccine Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 10-Valent Pneumococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 10-Valent Pneumococcal Polysaccharide Vaccine Market by Type
- 4.1 10-Valent Pneumococcal Polysaccharide Vaccine Type Introduction
- 4.1.1 Single Dose Vial
- 4.1.2 Pre-filled Syringe
- 4.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Type
- 4.2.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2021-2032)
- 4.2.3 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Type (2021-2032)
- 4.3 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Type
- 4.3.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Type (2021-2032)
- 4.3.3 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type (2021-2032)
5 10-Valent Pneumococcal Polysaccharide Vaccine Market by Application
- 5.1 10-Valent Pneumococcal Polysaccharide Vaccine Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Application
- 5.2.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2021-2032)
- 5.2.3 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Volume Share by Application (2021-2032)
- 5.3 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Application
- 5.3.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Application (2021-2032)
- 5.3.3 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application (2021-2032)
6 10-Valent Pneumococcal Polysaccharide Vaccine Regional Sales and Value Analysis
- 6.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2021-2032)
- 6.2.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2021-2026
- 6.2.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales by Region (2027-2032)
- 6.3 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Region (2021-2032)
- 6.4.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Region: 2021-2026
- 6.4.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Region (2027-2032)
- 6.5 Global 10-Valent Pneumococcal Polysaccharide Vaccine Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
- 6.6.2 North America 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
- 6.7.2 Europe 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
- 6.8.2 Asia-Pacific 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
- 6.9.2 South America 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value (2021-2032)
- 6.10.2 Middle East & Africa 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2025 VS 2032
7 10-Valent Pneumococcal Polysaccharide Vaccine Country-level Sales and Value Analysis
- 7.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2032)
- 7.3.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2021-2026)
- 7.3.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2027-2032)
- 7.4 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country (2021-2032)
- 7.4.1 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country (2021-2026)
- 7.4.2 Global 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.5.2 USA 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.9.2 France 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.16.2 China 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.19.2 India 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt 10-Valent Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 GSK
- 8.1.1 GSK Company Information
- 8.1.2 GSK Business Overview
- 8.1.3 GSK 10-Valent Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.1.4 GSK 10-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
- 8.1.5 GSK Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 10-Valent Pneumococcal Polysaccharide Vaccine Value Chain Analysis
- 9.1.1 10-Valent Pneumococcal Polysaccharide Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 10-Valent Pneumococcal Polysaccharide Vaccine Sales Mode & Process
- 9.2 10-Valent Pneumococcal Polysaccharide Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 10-Valent Pneumococcal Polysaccharide Vaccine Distributors
- 9.2.3 10-Valent Pneumococcal Polysaccharide Vaccine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst